After inking a related patent settlement last year, Viatris has cleared another obstacle in its quest to launch generic ...

Viatris Inc.'s proposed copy of Novo Nordisk A/S’ Wegovy doesn’t infringe a patent on using the once-weekly obesity drug ...

The Delaware court ruled that Viatris’ drug does not infringe the "administered without another therapeutic agent" limitation ...

A federal court ruled in Mylan's favor, finding no infringement of Novo's patent tied to Wegovy, rejecting direct, ...

Novo Nordisk's underperformance in recent weeks is attributed to a patent challenge by Viatris over its weight-loss therapy, Wegovy. Read more here.

Update 3:10pm: Adds Viatris comment. Novo Nordisk (NVO) ADRs pared some earlier gains, though remains up 1%, after the company lost a patent challenge related to the company's best-selling weight ...

If Viatris could sell generic versions of Wegovy and Ozempic, it'd be a major driver of new top-line growth. Sales of Ozempic brought in more than $3 billion for Novo Nordisk in the most recent ...

The office's Patent Trial and Appeal Board denied the requests by Mylan Pharmaceuticals, which is owned by Viatris, to review the validity of the Wegovy and Ozempic patents.

Viatris is trying to launch generic versions of Novo Nordisk's Ozempic and Wegovy. It should experience an uptick in growth soon, and the stock's valuation is cheap. It's important to keep ...

As of May 22, manufacturers are no longer allowed to distribute the compounded versions of semaglutide, which Novo Nordisk sells under the brand Wegovy for weight loss and Ozempic for diabetes.